Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction
Aim:The prevalence of airway obstruction varies widely with the definition used.Objectives:To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.Methods:We collected predicted values for fo...
Saved in:
Published in | Thorax Vol. 63; no. 12; pp. 1046 - 1051 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group Ltd and British Thoracic Society
01.12.2008
BMJ BMJ Publishing Group LTD |
Subjects | |
Online Access | Get full text |
ISSN | 0040-6376 1468-3296 1468-3296 |
DOI | 10.1136/thx.2008.098483 |
Cover
Loading…
Abstract | Aim:The prevalence of airway obstruction varies widely with the definition used.Objectives:To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.Methods:We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) and its lower limit of normal (LLN) from the literature. FEV1/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17–90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV1/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population.Results:The LLN for FEV1/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995–1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17–45% of men and 7–26% of women for GOLD; 0–18% of men and 0–16% of women for ATS/ERS; and 0–9% of men and 0–11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations.Conclusions:Airway obstruction should be defined by FEV1/FVC and FEV1 being below the LLN using appropriate reference equations. |
---|---|
AbstractList | The prevalence of airway obstruction varies widely with the definition used.
To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.
We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) and its lower limit of normal (LLN) from the literature. FEV(1)/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17-90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV(1)/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population.
The LLN for FEV(1)/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995-1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17-45% of men and 7-26% of women for GOLD; 0-18% of men and 0-16% of women for ATS/ERS; and 0-9% of men and 0-11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations.
Airway obstruction should be defined by FEV(1)/FVC and FEV(1) being below the LLN using appropriate reference equations. Aim:The prevalence of airway obstruction varies widely with the definition used.Objectives:To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.Methods:We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) and its lower limit of normal (LLN) from the literature. FEV1/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17–90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV1/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population.Results:The LLN for FEV1/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995–1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17–45% of men and 7–26% of women for GOLD; 0–18% of men and 0–16% of women for ATS/ERS; and 0–9% of men and 0–11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations.Conclusions:Airway obstruction should be defined by FEV1/FVC and FEV1 being below the LLN using appropriate reference equations. The prevalence of airway obstruction varies widely with the definition used.AIMThe prevalence of airway obstruction varies widely with the definition used.To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.OBJECTIVESTo study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) and its lower limit of normal (LLN) from the literature. FEV(1)/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17-90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV(1)/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population.METHODSWe collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) and its lower limit of normal (LLN) from the literature. FEV(1)/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17-90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV(1)/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population.The LLN for FEV(1)/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995-1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17-45% of men and 7-26% of women for GOLD; 0-18% of men and 0-16% of women for ATS/ERS; and 0-9% of men and 0-11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations.RESULTSThe LLN for FEV(1)/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995-1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17-45% of men and 7-26% of women for GOLD; 0-18% of men and 0-16% of women for ATS/ERS; and 0-9% of men and 0-11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations.Airway obstruction should be defined by FEV(1)/FVC and FEV(1) being below the LLN using appropriate reference equations.CONCLUSIONSAirway obstruction should be defined by FEV(1)/FVC and FEV(1) being below the LLN using appropriate reference equations. Aim: The prevalence of airway obstruction varies widely with the definition used. Objectives: To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations. Methods: We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV1 /FVC) and its lower limit of normal (LLN) from the literature. FEV1 /FVC from 40â[euro][per thousand]646 adults (including 13â[euro][per thousand]136 asymptomatic never smokers) aged 17-90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV1 /FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population. Results: The LLN for FEV1 /FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995-1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17-45% of men and 7-26% of women for GOLD; 0-18% of men and 0-16% of women for ATS/ERS; and 0-9% of men and 0-11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations. Conclusions: Airway obstruction should be defined by FEV1 /FVC and FEV1 being below the LLN using appropriate reference equations. |
Author | Miller, M R Quanjer, P H Schouten, J P Ruppel, G Swanney, M P Falaschetti, E Jensen, R L Stocks, J Enright, P L Pedersen, O F Crapo, R O Hankinson, J L |
Author_xml | – sequence: 1 givenname: M P surname: Swanney fullname: Swanney, M P email: maureen.swanney@cdhb.govt.nz organization: Respiratory Physiology Laboratory, Christchurch Hospital, Canterbury District Health Board, Christchurch, New Zealand – sequence: 2 givenname: G surname: Ruppel fullname: Ruppel, G email: maureen.swanney@cdhb.govt.nz organization: Pulmonary Function Laboratory, St Louis University Hospital, St Louis, Missouri, USA – sequence: 3 givenname: P L surname: Enright fullname: Enright, P L email: maureen.swanney@cdhb.govt.nz organization: College of Public Health, The University of Arizona, Tucson, Arizona, USA – sequence: 4 givenname: O F surname: Pedersen fullname: Pedersen, O F email: maureen.swanney@cdhb.govt.nz organization: Institute of Public Health, Aarhus University, Aarhus, Denmark – sequence: 5 givenname: R O surname: Crapo fullname: Crapo, R O email: maureen.swanney@cdhb.govt.nz organization: Pulmonary Division, LDS Hospital and University of Utah, Salt Lake City, Utah, USA – sequence: 6 givenname: M R surname: Miller fullname: Miller, M R email: maureen.swanney@cdhb.govt.nz organization: Department of Medicine, University Hospital Birmingham NHS Trust, Birmingham, UK – sequence: 7 givenname: R L surname: Jensen fullname: Jensen, R L email: maureen.swanney@cdhb.govt.nz organization: Pulmonary Division, LDS Hospital and University of Utah, Salt Lake City, Utah, USA – sequence: 8 givenname: E surname: Falaschetti fullname: Falaschetti, E email: maureen.swanney@cdhb.govt.nz organization: Department of Epidemiology and Public Health, University College London, London, UK – sequence: 9 givenname: J P surname: Schouten fullname: Schouten, J P email: maureen.swanney@cdhb.govt.nz organization: Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands – sequence: 10 givenname: J L surname: Hankinson fullname: Hankinson, J L email: maureen.swanney@cdhb.govt.nz organization: Valdosta, Georgia, USA – sequence: 11 givenname: J surname: Stocks fullname: Stocks, J email: maureen.swanney@cdhb.govt.nz organization: Portex Anaesthesia, Intensive Therapy and Respiratory Unit, UCL, Institute of Child Health, London, UK – sequence: 12 givenname: P H surname: Quanjer fullname: Quanjer, P H email: maureen.swanney@cdhb.govt.nz organization: Department of Pulmonary Diseases, Erasmus Medical Centre, Erasmus University, Rotterdam, The Netherlands |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20849756$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18786983$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkcFr2zAYxcXoWNNu592GYWyHgRPJsiX5uJmmG5SMwZrDLkKSpVWZbbWSTNv_vnKc5VAYOwn0fu_jfd87AyeDGzQAbxFcIoTJKt48LAsI2RLWrGT4BVigkrAcFzU5AQsIS5gTTMkpOAthBxOIEH0FThGjjNQML8DuOtjhdxZvdNa5e-2zzvY2Zs5kg_O96DLj_F5dX2zRar1tMi-idZnX7ah02Eu9DaoTIVhj1SQOk11Yfy8eMydD9KOafl-Dl0Z0Qb85vOfgen3xs_maX32__NZ8vsplhXHMTQVliZCkiEBcKVMaKGVNWylKLIyua9FiDGulkWaCwFJCyhiklCDSKgwNPgcf57m33t2NOkQ-BdRdJwbtxsDT4ggVGCfw_TNw50Y_pGwcUYZYQQpEE_XuQI2y1y2_9bYX_pH_vWECPhwAEZTojBeDsuHIFZCVNa1I4qqZU96F4LXhysb9vaIXtuMI8qlTnjrlU6d87jT5Vs98xwj_dOSzw4aoH4648H84oZhWfLNt-Kapyl8_4IZ_SfynmZf97r_DnwCD8b7e |
CODEN | THORA7 |
CitedBy_id | crossref_primary_10_1097_MCP_0000000000001023 crossref_primary_10_1186_s12875_021_01583_w crossref_primary_10_1002_ppul_24625 crossref_primary_10_1016_j_chest_2021_02_028 crossref_primary_10_1016_j_rmr_2012_09_020 crossref_primary_10_1002_ajim_23693 crossref_primary_10_1080_15412555_2019_1589443 crossref_primary_10_1378_chest_10_0992 crossref_primary_10_1088_1612_2011_10_7_075603 crossref_primary_10_1002_ajim_22366 crossref_primary_10_1186_1465_9921_13_13 crossref_primary_10_4103_lungindia_lungindia_477_24 crossref_primary_10_4103_1687_8426_153586 crossref_primary_10_1038_s41598_020_60478_5 crossref_primary_10_1080_07315724_2013_767652 crossref_primary_10_2174_1573398X18666220903121800 crossref_primary_10_3390_antiox10060883 crossref_primary_10_1007_s11897_014_0212_x crossref_primary_10_1080_10408444_2017_1315363 crossref_primary_10_1093_annweh_wxaa014 crossref_primary_10_1016_j_chemosphere_2018_12_079 crossref_primary_10_1016_j_prrv_2021_05_006 crossref_primary_10_1183_09031936_00193809 crossref_primary_10_1186_s12859_020_03785_y crossref_primary_10_1038_s41409_024_02265_8 crossref_primary_10_1109_TBME_2023_3250650 crossref_primary_10_1097_ACI_0000000000000146 crossref_primary_10_1016_j_chest_2024_08_048 crossref_primary_10_1021_acs_est_2c04972 crossref_primary_10_1186_s12890_017_0537_9 crossref_primary_10_35366_NTS191A crossref_primary_10_1002_ajim_22495 crossref_primary_10_1152_japplphysiol_00439_2019 crossref_primary_10_1186_s13104_015_1731_6 crossref_primary_10_1378_chest_10_0189 crossref_primary_10_3760_cma_j_issn_0366_6999_20121090 crossref_primary_10_1183_13993003_01499_2021 crossref_primary_10_1136_bmjresp_2023_001793 crossref_primary_10_1183_09031936_00135110 crossref_primary_10_1186_1745_6673_9_21 crossref_primary_10_1016_j_rmed_2013_04_008 crossref_primary_10_1080_15412555_2018_1531388 crossref_primary_10_3109_02770903_2013_860164 crossref_primary_10_1021_acsnano_1c09792 crossref_primary_10_3390_diagnostics13203261 crossref_primary_10_1093_occmed_kqaa023 crossref_primary_10_2147_COPD_S319220 crossref_primary_10_1016_j_arbres_2023_10_002 crossref_primary_10_26416_Pedi_62_2_2021_4890 crossref_primary_10_1210_clinem_dgaa296 crossref_primary_10_1183_20734735_0346_2018 crossref_primary_10_1007_s10772_019_09608_7 crossref_primary_10_1080_17476348_2017_1334553 crossref_primary_10_4046_trd_2016_79_3_121 crossref_primary_10_1183_23120541_00718_2022 crossref_primary_10_1002_ejhf_946 crossref_primary_10_1016_j_rmed_2023_107523 crossref_primary_10_1111_j_1440_1843_2010_01830_x crossref_primary_10_1097_MD_0000000000027124 crossref_primary_10_1186_s12889_024_17686_9 crossref_primary_10_3310_hta19360 crossref_primary_10_1002_ajim_23474 crossref_primary_10_1007_s00420_022_01922_z crossref_primary_10_33667_2078_5631_2022_20_16_22 crossref_primary_10_2217_cpr_14_28 crossref_primary_10_1183_09031936_00108409 crossref_primary_10_1513_AnnalsATS_201707_571OC crossref_primary_10_1128_spectrum_02139_21 crossref_primary_10_1136_bjsports_2022_106136 crossref_primary_10_1183_20734735_020117 crossref_primary_10_1080_15412555_2019_1566894 crossref_primary_10_1159_000508163 crossref_primary_10_1183_13993003_00918_2015 crossref_primary_10_1080_20018525_2024_2387405 crossref_primary_10_1093_eurheartj_eht192 crossref_primary_10_1002_clc_22802 crossref_primary_10_1016_j_cali_2017_05_001 crossref_primary_10_1177_1176934319888904 crossref_primary_10_1177_0272989X18824098 crossref_primary_10_1002_ajim_23244 crossref_primary_10_1183_09031936_00049909 crossref_primary_10_1177_1479164117746022 crossref_primary_10_3810_pgm_2010_09_2212 crossref_primary_10_4187_respcare_07069 crossref_primary_10_1016_j_envint_2016_05_006 crossref_primary_10_1136_bmjopen_2018_025132 crossref_primary_10_1371_journal_pone_0123626 crossref_primary_10_1016_S2213_2600_13_70086_9 crossref_primary_10_1016_j_rmr_2010_10_025 crossref_primary_10_1164_rccm_201608_1545OC crossref_primary_10_1016_j_rmr_2014_01_003 crossref_primary_10_1186_s40798_015_0021_0 crossref_primary_10_3945_ajcn_112_040774 crossref_primary_10_1016_j_ebiom_2024_105453 crossref_primary_10_1038_s41598_021_92911_8 crossref_primary_10_1186_s12890_023_02403_w crossref_primary_10_1155_2016_5478394 crossref_primary_10_1378_chest_10_1721 crossref_primary_10_2147_COPD_S232863 crossref_primary_10_1016_j_rmed_2017_12_004 crossref_primary_10_1080_02770903_2018_1531997 crossref_primary_10_1016_j_rmed_2011_01_008 crossref_primary_10_1080_03014460_2019_1572223 crossref_primary_10_2147_COPD_S377140 crossref_primary_10_3390_genes14040798 crossref_primary_10_4046_trd_2011_70_4_293 crossref_primary_10_1183_23120541_00110_2017 crossref_primary_10_2169_internalmedicine_50_4412 crossref_primary_10_3109_15412555_2011_626817 crossref_primary_10_1080_02770903_2022_2144349 crossref_primary_10_3402_ecrj_v2_27768 crossref_primary_10_1186_1471_2466_14_206 crossref_primary_10_1080_15412555_2020_1758050 crossref_primary_10_3109_15412555_2015_1048851 crossref_primary_10_1186_s12890_019_0976_6 crossref_primary_10_1080_0361073X_2018_1521374 crossref_primary_10_1183_09031936_00172908 crossref_primary_10_1378_chest_10_1117 crossref_primary_10_1183_20734735_0227_2023 crossref_primary_10_1186_1471_2466_10_35 crossref_primary_10_1164_rccm_200810_1540OC crossref_primary_10_1111_resp_12388 crossref_primary_10_1513_AnnalsATS_201710_830LE crossref_primary_10_1183_23120541_00084_2015 crossref_primary_10_1016_S0140_6736_15_60647_X crossref_primary_10_1183_09031936_00176811 crossref_primary_10_1016_j_envres_2020_109847 crossref_primary_10_1183_13993003_01575_2015 crossref_primary_10_4187_respcare_04965 crossref_primary_10_1183_09031936_00164608 crossref_primary_10_2196_resprot_7422 crossref_primary_10_15324_kjcls_2020_52_2_119 crossref_primary_10_1055_s_0040_1705662 crossref_primary_10_1183_13993003_02339_2014 crossref_primary_10_6000_1929_5634_2013_02_01_2 crossref_primary_10_1016_j_disamonth_2016_03_002 crossref_primary_10_1111_resp_12179 crossref_primary_10_1097_JOM_0b013e3181fc5e50 crossref_primary_10_1038_nrdp_2015_76 crossref_primary_10_2147_COPD_S338359 crossref_primary_10_3390_diagnostics11071189 crossref_primary_10_1164_rccm_201604_0871OC crossref_primary_10_1007_s12445_015_0131_4 crossref_primary_10_1183_09031936_00178109 crossref_primary_10_1111_resp_13262 crossref_primary_10_1016_S2213_2600_16_30149_7 crossref_primary_10_1093_ije_dyw318 crossref_primary_10_1159_000366064 crossref_primary_10_1186_2049_6958_5_6_437 crossref_primary_10_4187_respcare_07536 crossref_primary_10_1183_09031936_00134214 crossref_primary_10_1136_bmjopen_2018_023673 crossref_primary_10_3109_15412555_2013_773303 crossref_primary_10_1164_rccm_201511_2239ED crossref_primary_10_1016_j_rmed_2014_07_018 crossref_primary_10_1136_oemed_2013_101654 crossref_primary_10_1164_rccm_201701_0205OC crossref_primary_10_1111_resp_12855 crossref_primary_10_1371_journal_pone_0296470 crossref_primary_10_18857_jkpt_2018_30_3_96 crossref_primary_10_3109_15412555_2014_948998 crossref_primary_10_1007_s10055_023_00892_y crossref_primary_10_1038_srep28029 crossref_primary_10_1183_13993003_01585_2021 crossref_primary_10_1080_15412555_2019_1698530 crossref_primary_10_1002_acr_22686 crossref_primary_10_1136_oemed_2015_103406 crossref_primary_10_1183_13993003_00403_2018 crossref_primary_10_37349_eaa_2024_00031 crossref_primary_10_1183_09031936_00110010 crossref_primary_10_1080_10773525_2016_1176328 crossref_primary_10_1002_ajim_23445 crossref_primary_10_1016_j_rmed_2018_09_014 crossref_primary_10_1016_j_rmr_2013_11_007 crossref_primary_10_1038_s41556_021_00762_2 crossref_primary_10_1186_s12890_021_01590_8 crossref_primary_10_1111_resp_12040 crossref_primary_10_1080_15412555_2019_1641794 crossref_primary_10_1016_j_rmr_2010_09_007 crossref_primary_10_1139_h11_075 crossref_primary_10_1371_journal_pone_0205273 crossref_primary_10_1080_15412555_2017_1339681 crossref_primary_10_1097_HCR_0000000000000871 crossref_primary_10_1164_rccm_202311_2145OC crossref_primary_10_4103_1687_8426_203803 crossref_primary_10_1016_j_rmed_2011_06_012 crossref_primary_10_1158_1055_9965_EPI_21_1365 crossref_primary_10_1097_ACI_0b013e3283300baf crossref_primary_10_1371_journal_pone_0149760 crossref_primary_10_1164_rccm_201611_2282LE crossref_primary_10_1183_09031936_00190010 crossref_primary_10_1007_s10405_011_0521_7 crossref_primary_10_3109_15412555_2013_781996 crossref_primary_10_3390_s16081305 crossref_primary_10_9738_INTSURG_D_13_00060_1 crossref_primary_10_1183_13993003_00186_2019 crossref_primary_10_1136_thoraxjnl_2016_209665 crossref_primary_10_3109_02770903_2014_895012 crossref_primary_10_1093_hmg_ddv378 crossref_primary_10_2147_COPD_S295321 crossref_primary_10_1080_03009742_2023_2194105 crossref_primary_10_1136_thorax_2024_221813 crossref_primary_10_3238_arztebl_2014_0834 crossref_primary_10_1093_aje_kwz185 crossref_primary_10_2147_COPD_S361839 crossref_primary_10_1016_j_chest_2021_01_067 crossref_primary_10_1016_j_rmed_2020_106202 crossref_primary_10_1186_1465_9921_14_61 crossref_primary_10_1186_s12890_020_1091_4 crossref_primary_10_1016_j_resmer_2022_100891 crossref_primary_10_1016_j_pccm_2023_03_004 crossref_primary_10_1183_09031936_00126011 crossref_primary_10_1183_09059180_00003609 crossref_primary_10_2188_jea_JE20170220 crossref_primary_10_3390_toxics8030053 crossref_primary_10_3346_jkms_2024_39_e20 crossref_primary_10_1183_13993003_02129_2019 crossref_primary_10_1186_1471_2466_12_12 crossref_primary_10_1016_j_resp_2015_08_002 crossref_primary_10_1016_j_rmed_2010_12_017 crossref_primary_10_1164_rccm_201202_0366OC crossref_primary_10_2147_COPD_S382761 crossref_primary_10_1016_j_rmed_2018_04_011 crossref_primary_10_1056_NEJMc1914600 crossref_primary_10_1002_iid3_307 crossref_primary_10_4187_respcare_04650 crossref_primary_10_1183_09031936_00042215 crossref_primary_10_3233_JPD_212565 crossref_primary_10_1016_j_chest_2018_01_038 crossref_primary_10_1002_flm2_10 crossref_primary_10_1136_bmjresp_2020_000575 crossref_primary_10_2169_internalmedicine_49_3364 crossref_primary_10_1016_j_chest_2019_02_001 crossref_primary_10_1186_s40246_016_0076_0 crossref_primary_10_1016_j_rmr_2023_06_004 crossref_primary_10_1513_AnnalsATS_202103_284ST crossref_primary_10_17816_RFD2012429_34 crossref_primary_10_1080_15412555_2019_1653271 crossref_primary_10_4187_respcare_01816 crossref_primary_10_1016_j_rmed_2016_12_008 crossref_primary_10_1513_AnnalsATS_201703_194OC crossref_primary_10_1016_j_cardfail_2012_05_008 crossref_primary_10_1017_S0959259809990293 crossref_primary_10_1111_j_1440_1843_2010_01850_x crossref_primary_10_1111_resp_12771 crossref_primary_10_2147_JAA_S403645 crossref_primary_10_4046_trd_2017_80_2_105 crossref_primary_10_1164_rccm_201406_1166OC crossref_primary_10_1016_j_arbres_2022_11_014 crossref_primary_10_1016_j_mcna_2012_04_011 crossref_primary_10_1038_npjpcrm_2014_33 crossref_primary_10_1136_bmjopen_2011_000153 crossref_primary_10_1183_09031936_00107709 crossref_primary_10_1080_15412555_2024_2402706 crossref_primary_10_4187_respcare_05710 crossref_primary_10_1183_13993003_00635_2015 crossref_primary_10_1016_j_ejim_2013_01_008 crossref_primary_10_1007_s00059_019_4814_7 crossref_primary_10_1016_S0140_6736_14_60446_3 crossref_primary_10_1016_S2213_2600_17_30293_X crossref_primary_10_1136_thoraxjnl_2012_202810 crossref_primary_10_1016_j_alit_2019_04_009 crossref_primary_10_13066_kspm_2016_11_2_123 crossref_primary_10_4046_trd_2012_72_3_310 crossref_primary_10_1037_cpp0000256 crossref_primary_10_36416_1806_3756_e20210124 crossref_primary_10_1378_chest_09_2681 crossref_primary_10_1016_j_resinv_2014_08_002 crossref_primary_10_1186_s12882_017_0565_y crossref_primary_10_1186_1472_6963_11_37 crossref_primary_10_1136_thoraxjnl_2013_204460 crossref_primary_10_1038_s41598_020_73117_w crossref_primary_10_1111_jth_13525 crossref_primary_10_1183_13993003_00477_2019 crossref_primary_10_2471_BLT_18_216523 crossref_primary_10_3109_15412555_2014_922173 crossref_primary_10_1080_24745332_2022_2048980 crossref_primary_10_3389_fped_2019_00054 crossref_primary_10_18231_j_ijcap_2023_052 crossref_primary_10_1136_bmjopen_2018_028150 crossref_primary_10_1378_chest_10_2052 crossref_primary_10_1016_j_mtchem_2024_102024 crossref_primary_10_1111_resp_12793 crossref_primary_10_1136_bmjopen_2019_035885 crossref_primary_10_1183_09031936_00123613 crossref_primary_10_1016_j_jacc_2018_06_045 crossref_primary_10_1136_bmjresp_2020_000664 crossref_primary_10_4104_pcrj_2014_00006 crossref_primary_10_4187_respcare_04323 crossref_primary_10_3390_diagnostics11050785 crossref_primary_10_1016_j_rmed_2017_01_004 crossref_primary_10_1113_jphysiol_2014_282863 crossref_primary_10_1080_02770903_2018_1477956 crossref_primary_10_1155_2017_6287642 crossref_primary_10_1111_j_1440_1843_2009_01553_x crossref_primary_10_3109_15412555_2011_650802 crossref_primary_10_1016_j_hrtlng_2013_07_002 crossref_primary_10_4104_pcrj_2013_00048 crossref_primary_10_1111_resp_12540 crossref_primary_10_1183_09031936_00195512 crossref_primary_10_1024_0301_1526_a001168 crossref_primary_10_1093_icvts_ivz049 crossref_primary_10_1016_S2213_2600_14_70040_2 crossref_primary_10_1002_ajim_20792 crossref_primary_10_1016_j_cegh_2013_04_002 crossref_primary_10_1183_13993003_02325_2014 crossref_primary_10_2147_COPD_S280157 crossref_primary_10_1164_rccm_201201_0051OC crossref_primary_10_1080_17476348_2016_1190274 crossref_primary_10_1097_JOM_0b013e318229aaff crossref_primary_10_1186_s12890_019_0946_z crossref_primary_10_1016_j_ejim_2012_12_009 crossref_primary_10_1111_j_1440_1843_2011_01987_x crossref_primary_10_1183_09031936_00158212 crossref_primary_10_1097_JOM_0b013e31828b22cc crossref_primary_10_1183_09031936_00143209 crossref_primary_10_1056_NEJMoa1513737 crossref_primary_10_5320_wjr_v3_i3_57 crossref_primary_10_1186_s12940_018_0373_2 crossref_primary_10_1016_j_chest_2016_06_047 crossref_primary_10_1016_j_ccm_2020_06_004 crossref_primary_10_1183_09031936_00103309 crossref_primary_10_1378_chest_11_2718 crossref_primary_10_4103_lungindia_lungindia_300_18 crossref_primary_10_4236_ojanes_2015_53008 crossref_primary_10_1164_rccm_201306_1031LE crossref_primary_10_1331_JAPhA_2012_11100 crossref_primary_10_2147_JAA_S366453 crossref_primary_10_1016_j_jaip_2016_02_014 crossref_primary_10_23950_jcmk_10919 crossref_primary_10_3238_PersPneumo_2019_02_15_003 crossref_primary_10_1016_j_resp_2023_104094 crossref_primary_10_3402_ecrj_v3_30658 crossref_primary_10_1136_bmjopen_2014_005685 crossref_primary_10_1183_09031936_00074614 crossref_primary_10_1111_imj_14047 crossref_primary_10_1097_ADM_0000000000000103 crossref_primary_10_1186_1465_9921_11_180 crossref_primary_10_1016_S0027_9684_15_30623_4 crossref_primary_10_1088_1752_7155_7_1_017108 crossref_primary_10_1016_j_chest_2020_04_064 crossref_primary_10_1016_j_heliyon_2023_e20744 crossref_primary_10_1590_s1806_37562017000000276 crossref_primary_10_1183_09031936_00231414 crossref_primary_10_1183_09031936_00007711 crossref_primary_10_4187_respcare_01160 crossref_primary_10_1136_thoraxjnl_2020_216523 crossref_primary_10_1183_09059180_00005509 crossref_primary_10_1016_S1877_1203_10_70033_1 crossref_primary_10_1136_bmjresp_2023_002142 crossref_primary_10_1183_13993003_01878_2015 crossref_primary_10_1136_bmjopen_2013_002561 crossref_primary_10_1016_j_rmed_2019_08_004 crossref_primary_10_1186_s12931_018_0911_z crossref_primary_10_3399_bjgp18X700385 crossref_primary_10_2165_11535220_000000000_00000 crossref_primary_10_1186_s12889_015_2161_z crossref_primary_10_1164_rccm_201709_1861OC crossref_primary_10_1021_acsami_2c21680 crossref_primary_10_4103_0970_2113_116248 crossref_primary_10_1183_23120541_00034_2020 crossref_primary_10_1183_09031936_00019009 |
ContentType | Journal Article |
Copyright | 2008 BMJ Publishing Group and British Thoracic Society 2008 INIST-CNRS Copyright: 2008 2008 BMJ Publishing Group and British Thoracic Society |
Copyright_xml | – notice: 2008 BMJ Publishing Group and British Thoracic Society – notice: 2008 INIST-CNRS – notice: Copyright: 2008 2008 BMJ Publishing Group and British Thoracic Society |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR BTHHO CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1136/thx.2008.098483 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central BMJ Journals ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) BMJ Journals Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest One Academic Middle East (New) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-3296 |
EndPage | 1051 |
ExternalDocumentID | 4027206741 18786983 20849756 10_1136_thx_2008_098483 ark_67375_NVC_NC54ZQ0N_B thoraxjnl |
Genre | Multicenter Study Journal Article |
GeographicLocations | United Kingdom--UK England United States--US |
GeographicLocations_xml | – name: England – name: United Kingdom--UK – name: United States--US |
GroupedDBID | --- .55 .GJ .VT 08G 0R~ 123 18M 29Q 2WC 354 39C 3O- 4.4 40O 53G 5RE 5VS 6PF 7X7 7~S 88E 8F7 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL AAYEP ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGTL ACHTP ACMFJ ACOAB ACOFX ACQSR ACTZY ADBBV ADCEG ADZCM AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN BAWUL BENPR BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C45 CAG CCPQU COF CS3 CXRWF DIK DU5 E3Z EBS EJD F5P FEDTE FYUFA GX1 H13 HAJ HMCUK HVGLF HYE HZ~ IAO IEA IH2 IHR IOF ITC J5H KQ8 L7B M1P N4W N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W8F WH7 X7M YFH YOC YQY ZCG ZGI BSCLL AAYXX ACQHZ ADGHP AERUA CITATION PHGZM IQODW PJZUB PPXIY CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-b533t-f50b411b716035cf4f0bb97dba43afe99ad3309ce1e8a604b0788077616dc30f3 |
IEDL.DBID | 7X7 |
ISSN | 0040-6376 1468-3296 |
IngestDate | Tue Aug 05 09:42:54 EDT 2025 Sun Aug 17 05:41:00 EDT 2025 Thu Apr 03 06:56:51 EDT 2025 Mon Jul 21 09:15:54 EDT 2025 Thu Apr 24 23:06:21 EDT 2025 Tue Jul 01 02:30:50 EDT 2025 Tue Mar 18 09:38:07 EDT 2025 Thu Apr 24 23:02:55 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | Respiratory disease Anesthesia Airways obstruction Ratio Circulatory system Limit Cardiology Normal |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b533t-f50b411b716035cf4f0bb97dba43afe99ad3309ce1e8a604b0788077616dc30f3 |
Notes | istex:E109320FFB206D680C634135AD78AAB38BDF7CB3 PMID:18786983 Supplementary reference values data are published online only at http://thorax.bmj.com/content/vol63/issue12 local:thoraxjnl;63/12/1046 ark:/67375/NVC-NC54ZQ0N-B ArticleID:tx98483 href:thoraxjnl-63-1046.pdf ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://thorax.bmj.com/content/thoraxjnl/63/12/1046.full.pdf |
PMID | 18786983 |
PQID | 1781826217 |
PQPubID | 2041050 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_69811233 proquest_journals_1781826217 pubmed_primary_18786983 pascalfrancis_primary_20849756 crossref_citationtrail_10_1136_thx_2008_098483 crossref_primary_10_1136_thx_2008_098483 istex_primary_ark_67375_NVC_NC54ZQ0N_B bmj_primary_10_1136_thx_2008_098483 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2008-12-01 |
PublicationDateYYYYMMDD | 2008-12-01 |
PublicationDate_xml | – month: 12 year: 2008 text: 2008-12-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Thorax |
PublicationTitleAlternate | Thorax |
PublicationYear | 2008 |
Publisher | BMJ Publishing Group Ltd and British Thoracic Society BMJ BMJ Publishing Group LTD |
Publisher_xml | – name: BMJ Publishing Group Ltd and British Thoracic Society – name: BMJ – name: BMJ Publishing Group LTD |
References | Hansen, Sun, Wasserman 2007; 131 Cerveri, Corsico, Accordini 2008; 63 Roberts, Farber, Knox 2006; 130 Price, Tinkelman, Nordyke 2006; 129 Medbø, Melbye 2007; 101 Quanjer 1983; 19 2004; 23 Culver 2006; 51 Jones, Agusti 2006; 27 Quanjer, Tammeling, Cotes 1993; 6 Enright 2007; 62 Falaschetti, Laiho, Primatesta 2004; 23 Halbert, Isonaka, George 2003; 123 Perez-Padilla, Hallil, Vazquez-Garcia 2007; 4 Gräsbeck 2004; 42 Hnizdo, Glindmeyer, Petsonk 2006; 3 Celli, Halbert, Isonaka 2003; 22 Van Pelt, Borsboom, Rijcken 1994; 149 Pellegrino, Viegi, Brusasco 2005; 26 Lin, Watkins, Johnson 2008; 148 1991; 144 1987; 136 Viegi, Pedreschi, Pistelli 2000; 117 Shirtcliffe, Weatherall, Marsh 2007; 30 1997; 52 Fletcher, Peto 1977; 1 Siafakas, Vermeire, Pride 1995; 8 Hardie, Buist, Vollmer 2002; 20 Heath 2005; 330 Hankinson, Odencrantz, Fedan 1995; 152 Ferguson, Enright, Buist 2000; 117 Van der Lende, Orie 1972; 53 Lebowitz, Holberg 1990; 141 19020267 - Thorax. 2008 Dec;63(12):1031-2 |
References_xml | – volume: 144 start-page: 1202 year: 1991 article-title: Lung function testing: Selection of reference values and interpretative strategies. publication-title: Am Rev Respir Dis – volume: 23 start-page: 932 year: 2004 article-title: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. publication-title: Eur Respir J – article-title: Clinical Guideline 12. Chronic obstructive pulmonary disease February 2004. – volume: 63 start-page: 1040 year: 2008 article-title: Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. publication-title: Thorax – volume: 8 start-page: 1398 year: 1995 article-title: Optimal assessment and management of chronic obstructive pulmonary disease. A consensus statement of the European Respiratory Society (ERS). publication-title: Eur Respir J – volume: 42 start-page: 692 year: 2004 article-title: The evolution of the reference value concept. publication-title: Clin Chem Lab Med – volume: 117 start-page: 339S year: 2000 article-title: Prevalence of airways obstruction in a general population. European Respiratory Society vs. American Thoracic Society definition. publication-title: Chest – volume: 149 start-page: 1218 year: 1994 article-title: Discrepancies between longitudinal and cross-sectional change in ventilatory function in 12 years of follow-up. publication-title: Am J Respir Crit Care Med – volume: 53 start-page: 218 year: 1972 article-title: The MRC/ECCS questionnaire on respiratory symptoms: use in epidemiology. publication-title: Scand J Respir Dis – volume: 1 start-page: 1645 year: 1977 article-title: The natural history of chronic airflow obstruction. publication-title: BMJ – volume: 152 start-page: 179 year: 1995 article-title: Spirometric reference values from a sample of the general US population. publication-title: Am J Respir Crit Care Med – volume: 62 start-page: 1107 year: 2007 article-title: GOLD stage I is not a COPD risk factor. publication-title: Thorax – volume: 20 start-page: 1117 year: 2002 article-title: Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. publication-title: Eur Respir J – volume: 131 start-page: 349 year: 2007 article-title: Spirometric criteria for airway obstruction. Use percentage of FEV1/FVC ratio below the fifth percentile, not<70%. publication-title: Chest – volume: 141 start-page: 1491 year: 1990 article-title: Comparisons of spirometric reference values and the proportions of abnormal subjects among male smokers and those symptomatic in a community population. publication-title: Am Rev Respir Dis – volume: 27 start-page: 822 year: 2006 article-title: Outcomes and markers in the assessment of chronic obstructive pulmonary disease. publication-title: Eur Respir J – article-title: Download software and consult the associated documentation for full details (accessed 3 October 2008). – volume: 51 start-page: 719 year: 2006 article-title: Interpretation of spirometry: we can do better than the GOLD standard. publication-title: Chest – volume: 123 start-page: 1684 year: 2003 article-title: Interpreting COPD prevalence estimates: What is the true burden of disease? publication-title: Chest – volume: 129 start-page: 1531 year: 2006 article-title: Scoring system and clinical application of COPD diagnostic questionnaires. publication-title: Chest – volume: 6 start-page: 5 year: 1993 article-title: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. publication-title: Eur Respir J – volume: 23 start-page: 456 year: 2004 article-title: Prediction equations for normal and low lung function from the Health Survey for England. publication-title: Eur Respir J – volume: 26 start-page: 948 year: 2005 article-title: Interpretative strategies for lung function tests. Series “ATS/ERS Task Force: Standardisation of lung function testing”. publication-title: Eur Respir J – volume: 3 start-page: 1 year: 2006 article-title: Case definitions for chronic obstructive pulmonary disease. publication-title: COPD – volume: 130 start-page: 200 year: 2006 article-title: FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. publication-title: Chest – volume: 30 start-page: 232 year: 2007 article-title: COPD prevalence in a random population survey: a matter of definition. publication-title: Eur Respir J – volume: 4 start-page: 113 year: 2007 article-title: Impact of bronchodilator use on the prevalence of COPD in population-based samples. publication-title: COPD – volume: 136 start-page: 225 year: 1987 article-title: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. publication-title: Am Rev Respir Dis – volume: 52 start-page: 1 year: 1997 publication-title: Thorax – volume: 19 start-page: 1 year: 1983 article-title: Standardized lung function testing. Report Working Party ‘Standardization of lung function tests’ of ECCS. publication-title: Bull Europ Physiopath Respir – volume: 117 start-page: 1146 year: 2000 article-title: Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. publication-title: Chest – volume: 101 start-page: 1097 year: 2007 article-title: Lung function testing in the elderly—Can we still use the FEV1/FVC <70% as a criterion for COPD? publication-title: Respir Med – volume: 22 start-page: 268 year: 2003 article-title: Population impact of different definitions of airway obstruction. publication-title: Eur Respir J – volume: 330 start-page: 1461 year: 2005 article-title: Thresholds for normal blood pressure and serum cholesterol. publication-title: BMJ – volume: 148 start-page: 535 year: 2008 article-title: Screening for chronic obstructive pulmonary disease using spirometry: Summary of the evidence for the U.S. Preventive Services Task Force. publication-title: Ann Intern Med – reference: 19020267 - Thorax. 2008 Dec;63(12):1031-2 |
SSID | ssj0008117 |
Score | 2.469576 |
Snippet | Aim:The prevalence of airway obstruction varies widely with the definition used.Objectives:To study differences in the prevalence of airway obstruction when... Aim: The prevalence of airway obstruction varies widely with the definition used. Objectives: To study differences in the prevalence of airway obstruction when... The prevalence of airway obstruction varies widely with the definition used. To study differences in the prevalence of airway obstruction when applying four... The prevalence of airway obstruction varies widely with the definition used.AIMThe prevalence of airway obstruction varies widely with the definition used.To... |
SourceID | proquest pubmed pascalfrancis crossref istex bmj |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1046 |
SubjectTerms | Adolescent Adult Age Aged Aged, 80 and over Airway management Asymptomatic Biological and medical sciences Cardiology. Vascular system Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease, asthma Diagnostic Errors Female Forced Expiratory Volume - physiology Health care Health education Health surveys Humans Lung diseases Male Medical sciences Middle Aged Pneumology Practice Guidelines as Topic - standards Predictive Value of Tests Pulmonary Disease, Chronic Obstructive - diagnosis Reference Values Spirometry Vital Capacity - physiology Womens health Young Adult |
Title | Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction |
URI | https://api.istex.fr/ark:/67375/NVC-NC54ZQ0N-B/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/18786983 https://www.proquest.com/docview/1781826217 https://www.proquest.com/docview/69811233 |
Volume | 63 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fb9MwELZglRAv0_gdNoolEOIlNK6dxH5CrGqZkBYBYlXFi2UnjtjWJaMpYvz33Llupj0MHqPLWdbd2f5sf74j5LVwgNrT1MZGqToWJWOxqioVcy6EEmNhVIU3usdFdnQiPi3SRThw6wKtcjsn-om6aks8Ix-xXCIUBgT9_vJnjFWj8HY1lNC4SwaYugw3X_mi33Al-Ihyy5rLYCSF1D6MZ6P1j6tApFRS-JyB9uLsxto0QDNfIVfSdGCuelPn4nYg6hek2R7ZDUiSfti4_gG545qH5N5xuCt_RM48G4ACwKNLLIVGl_iWibY1bRCnLinAVS-dTedsNJtPqA8GusJkrq7zIgiCEuE18om8C1HdnK5-mz-0tX3u2cfkZDb9NjmKQ2WF2AK8W8d1mljBmM2xyHRa1qJOrFV5ZY3gpnZKmYrzRJWOOWmyRFgAEhIT_7CsKnlS8ydkp2kb94xQA_jHlJU0nBmhxk65hNvMSgNASeZWRuQVWFZfbnJnaL_n4JkG-4cKmN7-EXm3tbwuQ3JyrJGxvF3hba_w37bfeFf2_5nVOdLZ8lQX84kuJqn4_iUp9GFEhjd83SuMEylUnmYROdg6X4eh3unrwIzIy16M_kH6WuPaX53OFITimENXnm5C5rrPMpcg5c__3fQ-ue-JKp5Hc0B2wL_uBaChtR36kB-SweG0-PwVvj4u2F8jYgZ_ |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKKwEXxJtAaS3xEJewSewk9gEhWLra0m4kpHa16sXYiSMoy6ZsFrX9U_xGZpxH1UPh1LMzljUz9nwTf54h5CW3gNrj2PhaytLneRj6siikzxjnkkdcywJvdCdZMj7kn2fxbI386d7CIK2yOxPdQV1UOf4jH4SpQCgMCPr9yS8fu0bh7WrXQqNxiz17fgopW_1u9xPY91UUjXYOhmO_7SrgG4A2K7-MA8PD0KTYYDnOS14Gxsi0MJozXVopdQE5vsxtaIVOAm4giAosehMmRc6CksG8N8gGBN4AKYTprE_wAny02bH0Eti5bSmhkCWD1bezlrgpBXc1Cs3P40uxcAPNeobcTF2Decqmr8bVwNcFwNFdcqdFrvRD42r3yJpd3Cc3J-3d_ANy7NgHFAAlnWPrNTrHt1O0KukCcfGcAjx2o6OdaTgYTYfUOR9dYvFYW7shcLoc4Tzyl5zLoLj-vjzV57Qyfa3bh-TwWnT-iKwvqoV9QqgGvKXzQmgWai4jK23ATGKEBmAmUiM88gI0q06aWh3K5TgsUaD_tuOm079H3naaV3lbDB17csyvFnjTC_x37tfOlP13evkD6XNprLLpUGXDmB99CTL10SNbl2zdC0SB4DKNE49sdsZX7dFSq4uN4JHtfhjtg3S5ha1-1yqR4IoRg6U8blzmYs0iFTDKnv576m1ya3ww2Vf7u9neM3LbkWQch2eTrIOt7XNAYiuz5dyfkq_Xvd_-AutzQHM |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKK1VcEG8CpbXEQ1zCJrGT2AeEYNuopTQCia5WvRg7cQRlScruorZ_jV_HjPOoeiicep6MZc3D_hx_niHkObeA2uPY-FrKyudFGPqyLKXPGOeSR1zLEm90D_Jk95B_mMbTFfKnfwuDtMp-TXQLddkU-I98FKYCoTAg6FHV0SI-bWdvT3752EEKb1r7dhptiOzb81M4vi3e7G2Dr19EUbbzZbzrdx0GfAMwZ-lXcWB4GJoUmy3HRcWrwBiZlkZzpisrpS7hvC8LG1qhk4Ab2FAFFsAJk7JgQcVg3BtkLWWwbUIupdPhsBfgA86esZdAFndlhUKWjJbfzjoSpxTc1Ss0P48v7Ytr6OIz5GnqBbiqantsXA2C3WaY3Sa3OhRL37Vhd4es2PouWT_o7unvkWPHRKAALukM27DRGb6jok1Fa8TIMwpQ2UmznUk4yiZj6gKRzrGQrF04EQRggdAeuUwufFBdf5-f6nPamKHu7X1yeC02f0BW66a2jwjVgL10UQrNQs1lZKUNmEmM0ADSRGqER56BZdVJW7dDufMOSxTYv-u-6ezvkde95VXRFUbH_hyzqxVeDQr_Hfulc-XwnZ7_QCpdGqt8Mlb5OOZHn4NcvffI5iVfDwpRILhM48QjG73zVbfMLNRFUnhkaxCjf5A6V9vm90IlEkIxYjCVh23IXMxZpAKk7PG_h94i65Bp6uNevv-E3HR8GUfn2SCr4Gr7FEDZ0my66Kfk63Wn218KB0Sp |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Using+the+lower+limit+of+normal+for+the+FEV1%2FFVC+ratio+reduces+the+misclassification+of+airway+obstruction&rft.jtitle=Thorax&rft.au=Swanney%2C+M+P&rft.au=Ruppel%2C+G&rft.au=Enright%2C+P+L&rft.au=Pedersen%2C+O+F&rft.date=2008-12-01&rft.pub=BMJ+Publishing+Group+LTD&rft.issn=0040-6376&rft.eissn=1468-3296&rft.volume=63&rft.issue=12&rft.spage=1046&rft_id=info:doi/10.1136%2Fthx.2008.098483&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4027206741 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0040-6376&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0040-6376&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0040-6376&client=summon |